title: Similar Neutrophil-Driven Inflammatory and Antibacterial Responses in Elderly Patients with Symptomatic and Asymptomatic Bacteriuria.
abstract: Differential diagnosis of asymptomatic bacteriuria (ASB) and urinary tract infection (UTI) is based on the presence of diverse symptoms, including fever (≥38.5°C), rigors, malaise, lethargy, flank pain, hematuria, suprapubic discomfort, dysuria, and urgent or frequent urination. There is consensus in the medical community that ASB warrants antibiotic treatment only for patients undergoing urological procedures that lead to mucosal bleeding, catheterized individuals whose ASB persists for more than 48 h after catheter removal, and pregnant women. Pyuria is associated with UTI and implicates host immune responses via release of antibacterial effectors and phagocytosis of pathogens by neutrophils. Such responses are not sufficiently described for ASB. Metaproteomic methods were used here to identify the pathogens and evaluate molecular evidence of distinct immune responses in cases of ASB compared to UTI in elderly patients who were hospitalized upon injury. Neutrophil-driven inflammatory responses to invading bacteria were not discernible in most patients diagnosed with ASB compared to those with UTI. In contrast, proteomic urine analysis for trauma patients with no evidence of bacteriuria, including those who suffered mucosal injuries via urethral catheterization, rarely showed evidence of neutrophil infiltration. The same enzymes contributing to the synthesis of leukotrienes LTB4 and LTC4, mediators of inflammation and pain, were found in the UTI and ASB cohorts. These data support the notion that the pathways mediating inflammation and pain in most elderly patients with ASB are not quantitatively different from those seen in most elderly patients with UTI and warrant larger clinical studies to assess whether a common antibiotic treatment strategy for elderly ASB and UTI patients is justified.
authors.affiliation: The J. Craig Venter Institute, Rockville, Maryland, USA.
authors.forename: Yanbao
authors.initials: Y
authors.lastname: Yu
authors.affiliation: Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Martin D
authors.initials: MD
authors.lastname: Zielinski
authors.affiliation: The J. Craig Venter Institute, Rockville, Maryland, USA.
authors.forename: Melanie A
authors.initials: MA
authors.lastname: Rolfe
authors.affiliation: Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Melissa M
authors.initials: MM
authors.lastname: Kuntz
authors.affiliation: Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
authors.forename: Heidi
authors.initials: H
authors.lastname: Nelson
authors.affiliation: The J. Craig Venter Institute, Rockville, Maryland, USA.
authors.forename: Karen E
authors.initials: KE
authors.lastname: Nelson
authors.affiliation: The J. Craig Venter Institute, Rockville, Maryland, USA rpieper@jcvi.org.
authors.forename: Rembert
authors.initials: R
authors.lastname: Pieper
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D058345:Asymptomatic Infections / Q000628:therapy*; D001437:Bacteriuria / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D009504:Neutrophils / Q000276:immunology*; D011446:Prospective Studies; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents